1997 Annual Report
Product Review Financials Setting
  | Financial Highlights | Financial Review |
| Management’s Report | Audit Committee’s Report |
| Independent Auditors’ Report | Financial Statements
| Notes to Financial Statements |
| Directors, Committees, and Officers |
| Corporate and Shareholder Information |
| Consolidated Income |
| Consolidated Balance Sheet |
| Consolidated Shareholder’s Equity |
| Consolidated Cash Flows |
| Segment Information | Geographic Data |
| Quarterly Data | Financial Summary |
 

  Consolidated Statement of Cash Flows
  Pfizer Inc and Subsidiary Companies

  Year ended December 31     
(millions of dollars)
 
1997
 
1996
 
1995 
Operating Activities            
  • Net income
  •  $ 2,213  $ 1,929  $ 1,573 
  • Adjustments to reconcile net income to net cash provided by operating activities:
  •            
    • Depreciation and amortization of intangibles
      502   430   374 
    • Deferred taxes and other
      24   89   64 
    • Changes in assets and liabilities, net of effect of businesses acquired and divested:
               
    Accounts receivable   (503)   (255)   (290) 
    Inventories   (375)   (149)   (25) 
    Prepaid and other assets   (138)   (208)   (171) 
    Accounts payable and accrued liabilities   (26)   66   320 
    Income taxes payable   (127)   23   88 
    Other deferred items   59   142   (112) 
  • Net cash provided by operating activities
  •   1,629   2,067   1,821 
    Investing Activities            
  • Purchases of property, plant and equipment
  •   (943)   (774)   (696) 
  • Purchases of short-term investments
  •   (221)   (2,851)   (2,611) 
  • Proceeds from redemptions of short-term investments
  •   29   3,490   2,185 
  • Purchases of long-term investments
  •   (76)   (820)   (151) 
  • Purchases and redemptions of short-term investments by financial subsidiaries
  •   45   (11)   (30) 
  • (Increase)/decrease in loans and long-term investments by financial subsidiaries
  •   (20)   52   330 
  • Acquisitions, net of cash acquired
  •     (451)   (1,521) 
  • Proceeds from the sale of a businesses
  •   21   353   — 
  • Other investing activities
  •   143   75   151 
  • Net cash used in investing activities
  •   (1,022)   (937)   (2,343) 
    Financing Activities            
  • Proceeds from issuances of long-term debt
  •   57   636   502 
  • Repayments of long-term debt
  •   (269)   (804)   (52) 
  • Increase/(decrease) in short-term debt
  •   370   259   (444) 
  • Purchases of common stock
  •   (586)   (27)   (108) 
  • Cash dividends paid
  •   (881)   (771)   (659) 
  • Stock option transactions
  •   411   280   205 
  • Other financing activities
  •   50   45   37 
  • Net cash used in financing activities
  •   (848)   (382)   (519) 
  • Effect of exchange rate changes on cash and cash equivalents
  •   (32)   (1)   (14)
  • Net increase/(decrease) in cash and cash equivalents
  •   (273)   747   (1,055) 
  • Cash and cash equivalents at beginning of year
  •   1,150   403   1,458 
    Cash and cash equivalents at end of year  $ 877  $ 1,150  $ 403 
    Supplemental Cash Flow Information            
  • Cash paid during the period for:
  •            
    • Income taxes
     $ 856  $ 709  $ 646 
    • Interest
      151   139   175 
    See Notes to Consolidated Financial Statements which are an integral part of these statements.
      letter back top next
      Logo Imagemap
      intended for investors
      Advisory Information for Investors
      Copyright © 1997, 1998 Pfizer Inc All rights reserved.